What is HC Wainwright’s Estimate for AQST FY2027 Earnings?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Aquestive Therapeutics in a report issued on Monday, March 9th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.52) for the year. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.46) per share.

AQST has been the subject of a number of other reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Wednesday, January 21st. Lake Street Capital set a $6.00 price objective on Aquestive Therapeutics in a research report on Tuesday, February 3rd. Finally, Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST opened at $4.29 on Tuesday. The business’s fifty day moving average price is $4.17 and its two-hundred day moving average price is $5.22. The stock has a market cap of $523.55 million, a PE ratio of -5.50 and a beta of 1.61. Aquestive Therapeutics has a one year low of $2.12 and a one year high of $7.55.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, March 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). The company had revenue of $13.02 million during the quarter, compared to analysts’ expectations of $13.28 million.

Institutional Investors Weigh In On Aquestive Therapeutics

Hedge funds have recently made changes to their positions in the business. Commonwealth Equity Services LLC acquired a new position in shares of Aquestive Therapeutics during the 3rd quarter valued at about $5,918,000. Pale Fire Capital SE boosted its position in shares of Aquestive Therapeutics by 25.5% in the second quarter. Pale Fire Capital SE now owns 1,676,451 shares of the company’s stock worth $5,549,000 after acquiring an additional 340,767 shares during the last quarter. Aberdeen Group plc purchased a new stake in Aquestive Therapeutics in the third quarter valued at approximately $3,494,000. Sio Capital Management LLC grew its holdings in Aquestive Therapeutics by 141.9% in the second quarter. Sio Capital Management LLC now owns 947,489 shares of the company’s stock valued at $3,136,000 after purchasing an additional 555,860 shares during the period. Finally, Diametric Capital LP acquired a new position in Aquestive Therapeutics during the second quarter worth approximately $547,000. Institutional investors and hedge funds own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.